NOW APPROVED FOR CHRONIC MIGRAINE

More info to come. Content beyond homepage is specific to EM. For CM, please see the Prescribing Information.

Request Samples

Patient Savings

Request a rep
POWERFUL
REDUCTIONS
CONTINUOUS
CONTROL*
SAFE AND
WELL TOLERATED

Across 12 weeks with QULIPTA® 60 mg:

PROVEN EFFICACY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE1

  • EM primary endpoint: Significant -4.2 migraine day reduction from 7.8 baseline (n=222) vs -2.5 from 7.5 baseline for placebo (n=214); P<0.0011,2‡
  • CM primary endpoint: Significant -6.9 migraine day reduction from 19.2 baseline (n=256) vs -5.1 from 18.9 for placebo (n=246); P<0.0011§

MAJORITY OF EM PATIENTS (61%) TAKING QULIPTA 60 mg ACHIEVED A 50% TO 100% REDUCTION IN MONTHLY MIGRAINE DAYS1‡

  • Zero migraine days—up to 100% reduction achieved3

LIMITATIONS: In the 12-week EM pivotal study, 100% response rate was a pre-specified, non-ranked endpoint and was not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

 

Across 12 weeks with QULIPTA® 60 mg (EM):

MIGRAINE DAY REDUCTIONS CONTINUED ACROSS 12 WEEKS3‡

  • Reductions observed as early as Day 1 after the first dose2

CONTINUOUS REDUCTIONS OBSERVED ACROSS 52 WEEKS3¶

LIMITATIONS:

  • In the 12-week EM pivotal study, Day 1 after the first dose was a pre-specified, non-ranked endpoint and was not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.
  • Data from the 52-week EM open-label safety study have limitations as the study was not blinded, not controlled, and included inherent self-selection bias for remaining in the trial. Results should be interpreted with these factors in mind.

 

 

Across 12 weeks with QULIPTA®:

ESTABLISHED SAFETY‡§

  • The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence1

 

 

ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS $0†

The recommended dosage of QULIPTA for chronic migraine is 60 mg taken once daily.

Chronic Migraine Dose Modifications

DRUG INTERACTIONS

  • Avoid use with Strong CYP3A4 Inhibitors or CYP3A4 Inducers.

USE IN SPECIFIC POPULATIONS

  • Severe Renal Impairment or End-Stage Renal Disease: avoid use
  • Avoid use in patients with severe hepatic impairment
*

Specific to episodic migraine.

†

Eligibility: Available to patients with commercial insurance coverage for QULIPTA® (atogepant) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com. For additional information, call 1-855-QULIPTA (1-855-785-4782). To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie.

‡

Data from Phase 3 ADVANCE EM pivotal study.

§

Data from Phase 3 PROGRESS CM pivotal study.

Data from 52-week, open-label, long term safety study for EM.

†

CGRP=calcitonin gene-related peptide; CM=chronic migraine; EM=episodic migraine.

†

EM Study design: Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month.1

†

CM Study design: A randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 15 or more migraine days per month.1